Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Twist Bioscience Corp — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.82, while Twist Bioscience Corp trades at $93.82 (market cap $5.97B). Which is the better fit depends on your goals.
| PDBC | TWST | |
|---|---|---|
52-Week High | $18.91 | $102.88 |
52-Week Low | $12.90 | $24.16 |
Market Cap | — | $5.97B |
Sector | — | Health |
Enterprise Value | — | $5.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF, trades at $17.65, up 2.32% today, reflecting strong commodity momentum. The technical outlook is bullish with moving averages signaling strength, though RSI levels suggest potential overbought conditions. Recent news highlights institutional accumulation, such as Geneos Wealth Management increasing its stake by 150.6% in Q1 2026 (Defense World, 2026-07-19). The fund has delivered significant returns, up 37% since March 2024, driven by energy price surges and supply disruptions.
The outlook for PDBC remains positive as a diversified commodities play and inflation hedge, but risks include commodity price volatility and the fund's structural costs. Momentum may weaken if oil prices retreat, as noted in a recent downgrade to hold (Seeking Alpha, 2026-06-11). Investors should weigh the fund's tax advantages against roll costs and cyclical commodity exposure.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
